These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25698772)

  • 1. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
    Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
    J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.
    Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K
    J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis.
    Koomanachai P; Landersdorfer CB; Chen G; Lee HJ; Jitmuang A; Wasuwattakul S; Sritippayawan S; Li J; Nation RL; Thamlikitkul V
    Antimicrob Agents Chemother; 2014; 58(1):440-6. PubMed ID: 24189256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.
    Markou N; Fousteri M; Markantonis SL; Zidianakis B; Hroni D; Boutzouka E; Baltopoulos G
    J Antimicrob Chemother; 2012 Oct; 67(10):2459-62. PubMed ID: 22790220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.
    Karaiskos I; Friberg LE; Galani L; Ioannidis K; Katsouda E; Athanassa Z; Paskalis H; Giamarellou H
    Int J Antimicrob Agents; 2016 Sep; 48(3):337-41. PubMed ID: 27474468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.
    Marchand S; Lamarche I; Gobin P; Couet W
    J Antimicrob Chemother; 2010 Aug; 65(8):1753-8. PubMed ID: 20507861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
    Li J; Coulthard K; Milne R; Nation RL; Conway S; Peckham D; Etherington C; Turnidge J
    J Antimicrob Chemother; 2003 Dec; 52(6):987-92. PubMed ID: 14585859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
    Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.
    Luque S; Escaño C; Sorli L; Li J; Campillo N; Horcajada JP; Salas E; Grau S
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa.
    Luque S; Sorli L; Li J; Collado S; Barbosa F; Berenguer N; Horcajada JP; Grau S
    J Chemother; 2014 Apr; 26(2):122-4. PubMed ID: 24090909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients.
    Magréault S; Mankikian J; Marchand S; Diot P; Couet W; Flament T; Grégoire N
    J Cyst Fibros; 2020 May; 19(3):421-426. PubMed ID: 31501050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers.
    Couet W; Grégoire N; Gobin P; Saulnier PJ; Frasca D; Marchand S; Mimoz O
    Clin Pharmacol Ther; 2011 Jun; 89(6):875-9. PubMed ID: 21544080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.
    Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O
    J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.
    Bouchene S; Marchand S; Couet W; Friberg LE; Gobin P; Lamarche I; Grégoire N; Björkman S; Karlsson MO
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):407-422. PubMed ID: 29665289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing guidance for intravenous colistin in critically-ill patients.
    Nation RL; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Forrest A; Paterson DL; Li J; Silveira FP
    Clin Infect Dis; 2017 Mar; 64(5):565-571. PubMed ID: 28011614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
    Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.
    Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT
    J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
    Plachouras D; Karvanen M; Friberg LE; Papadomichelakis E; Antoniadou A; Tsangaris I; Karaiskos I; Poulakou G; Kontopidou F; Armaganidis A; Cars O; Giamarellou H
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3430-6. PubMed ID: 19433570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.